Large cell carcinoma of the lung pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 69: Line 69:
{{familytree | | | | | | | | | |!| | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | }}
{{familytree | | | | | | | | | C01 | | | | | | | | | C01=Neuroendocrine hyperplasia}}
{{familytree | | | | | | | | | C01 | | | | | | | | | C01=Neuroendocrine hyperplasia}}
{[familytree/end}}
** The other hypothesis is that neuroendocrine hyperplasia and SCLC arise from a less‐differentiated progenitor‐like cell.
** The other hypothesis is that neuroendocrine hyperplasia and SCLC arise from a less‐differentiated progenitor‐like cell.



Revision as of 19:05, 27 February 2018

Large Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Large Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Large cell carcinoma of the lung pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Large cell carcinoma of the lung pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Large cell carcinoma of the lung pathophysiology

CDC on Large cell carcinoma of the lung pathophysiology

Large cell carcinoma of the lung pathophysiology in the news

Blogs on Large cell carcinoma of the lung pathophysiology

Directions to Hospitals Treating Large cell carcinoma of the lung

Risk calculators and risk factors for Large cell carcinoma of the lung pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Large cell carcinoma of the lung arises from the epithelial cells of the lung, which are usually involved in the lining of the airways. The pathological irritation causes the mucus-secreting ciliated pseudostratified columnar respiratory epithelial cells to be replaced by stratified squamous epithelium. Large cell carcinoma of the lung has a peripheral location, and usually appears as a well-circumcised mass attached to the thoracic wall. Large cell carcinoma of the lung is a rapidly growing cancer. The histologic subtype of large cell neuroendocrine tumor is related with a more aggressive presentation. Genes involved in the pathogenesis of large cell carcinoma of the lung, include: EGFR, LKB1, KRAS, HER2, and ALK. On gross pathology, large cell carcinoma of the lung is characterized by well-defined borders, spherical morphology, homogeneous gray-white surface, and bulging appearance. On micropathology, large cell carcinoma of the lung is characterized by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. On immunohistochemistry characteristic features of large cell carcinoma of the lung, include: loss of staining with CK5/6, and positive immunoreactivity to EGFR, PDGFR-alpha, and c-kit.[1]

Pathogenesis

  • Large cell carcinoma of the lung arises from the epithelial cells of the lung, which are usually involved in the lining of the airways
  • The pathological irritation causes the mucus-secreting ciliated pseudostratified columnar respiratory epithelial cells to be replaced by stratified squamous epithelium.
  • Large cell carcinoma of the lung has a peripheral location, and usually appears as a well-circumcised mass attached to the thoracic wall
  • Large cell carcinoma of the lung is a rapidly growing cancer
  • The histologic subtype of large cell neuroendocrine tumor is related with a more aggressive presentation[1]

Precursor lesions

  • There are no precursor lesions associated with most of the types of large cell carcinoma except for basaloid carcinoma.
Type of LCC Precursor lesions
Adjacent squamous dysplasia
  • Adjacent squamous dysplasia
  • Bronchial preneoplastic lesions
Lymphoepithelioma-like carcinoma
  • EBV viral infection (viral (EBER1) dependent transformation)

Histogenesis

  • Large cell carcinomas (LCC) commonly originate from a pluripotent progenitor cells.
  • The tumour subtypes of LCC generally follows a proximal‐to‐distal distribution pattern moving distally from the trachea.
  • Lung tumours initiated by oncogenic K‐Ras activation appeared to be derived from cells located in the bronchioalveolar duct junction (BADJ).

Role of BASCs in large cell carcinoma

  • Bronchioalveolar duct junction (BADJ) contains cells that expresses both Clara‐specific and alveolar‐specific markers.
  • These cells are bronchioalveolar stem cells (BASCs).
  • Activation of K‐Ras results in differentiation of BASC's leading to adenoma formation.
 
 
 
 
 
 
 
 
 
BASC
Dual positive cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K‐Ras activation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adenoma formation
 
 
 
 
 
 
 
Tumor markers for Lung carcinoma
  • CD133 (prominin-1)
  • CD44 (membrane-bound glycoprotein)
  • CD133+ESA+
  • CD90
  • CD87 (uPAR)
  • CD166+CD44+ and CD166+EpCAM+

Two hypotheses explaining the origin of NE variants of large cell carcinoma

  • Neuroendocrine bodies (NEBs) are cellular bodies in the epithelial lining of the bronchi.
  • Neuroendocrine bodies (NEBs) harbour pulmonary neuroendocrine cells (PNECs).
  • PNECs are associated with variant Clara expressing cells (vCEs).
    • One hypothesis is neuroendorcrine tumours arise from PNECs.

{[familytree/end}}

    • The other hypothesis is that neuroendocrine hyperplasia and SCLC arise from a less‐differentiated progenitor‐like cell.

Genetics

  • Development of large cell carcinoma of the lung is the result of multiple genetic mutations[1]
  • Genetic mutations play an important role in the treatment selection for large cell carcinoma of the lung
  • Genes involved in the pathogenesis of large cell carcinoma of the lung, include:[2]

Associated Conditions

  • Conditions associated with large cell carcinoma of the lung, include:[3]
  • Paraneoplasic syndromes, such as:

Gross Pathology

  • On gross pathology, findings associated with large cell carcinoma of the lung, include:[4]
  • Well-defined borders
  • Spherical morphology
  • Homogeneous gray-white surface
  • Bulging appearance
  • Size greater than 4cm

Microscopic Pathology

  • On microscopic pathology, findings associated with large cell carcinoma of the lung, include:[4]
  • Larger size of the anaplastic cells
  • A higher cytoplasmic-to-nuclear size ratio
  • Lack of "salt-and-pepper" chromatin
  • On inmunohistochemistry, findings associated with large cell carcinoma of the lung, include:[4]
  • Loss of staining with CK5/6
  • Positive immunoreactivity to EGFR, PDGFR-alpha, and c-kit

Gallery

References

  1. 1.0 1.1 1.2 Davidson MR, Gazdar AF, Clarke BE (2013). "The pivotal role of pathology in the management of lung cancer". J Thorac Dis. 5 Suppl 5: S463–78. doi:10.3978/j.issn.2072-1439.2013.08.43. PMC 3804871. PMID 24163740.
  2. Shi WY, Liu KD, Xu SG, Zhang JT, Yu LL, Xu KQ, Zhang TF (2014). "Gene expression analysis of lung cancer". Eur Rev Med Pharmacol Sci. 18 (2): 217–28. PMID 24488911.
  3. Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (2014). "Paraneoplastic syndromes associated with lung cancer". World J Clin Oncol. 5 (3): 197–223. doi:10.5306/wjco.v5.i3.197. PMC 4127595. PMID 25114839.
  4. 4.0 4.1 4.2 Miller YE (2005). "Pathogenesis of lung cancer: 100 year report". Am. J. Respir. Cell Mol. Biol. 33 (3): 216–23. doi:10.1165/rcmb.2005-0158OE. PMC 2715312. PMID 16107574.


Template:WikiDoc Sources

 
 
 
 
 
 
 
 
Pulmonary neuroendocrine cells(variant Clara expressing cells)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Loss of Rb1 + Trp53 function
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuroendocrine hyperplasia